お知らせ • Apr 15
Lantern Pharma Inc. Launches withZeta.ai, the Worlds First Multi Agentic AU Co Scientist for Rare Cancer Drug Discovery and Development
Lantern Pharma Inc. announced that withZeta.ai—the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development—is now commercially live and actively onboarding subscribers. Subscriptions are available immediately at withzeta.ai, spanning introductory, academic, and commercial tiers, and represent a new, non-dilutive revenue stream for Lantern Pharma shareholders. The platform’s commercial debut will be showcased through two landmark events: a private investor briefing at Nasdaq MarketSite in New York City on April 16, 2026, and public demonstrations at the American Association for Cancer Research Annual Meeting 2026 in San Diego at Booth 5054 during April 17–22. withZeta.ai is the next generation of the AI platform technologies from RADR®, an oncology focused experimental biology and molecular analysis platform Lantern Pharma has built for its own cancer programs—and is now making available to the broader drug discovery and research communities. The Nasdaq MarketSite Debut—April 16, 2026. Lantern Pharma will host an exclusive live demonstration of withZeta.ai at Nasdaq MarketSite in New York City—one of the world’s most recognized venues for presenting innovation to the financial and biotech investment community. The event will bring together 25 of the biotech industry’s leading investors, analysts, and media professionals for a first-hand experience of the platform in action, including live multi-agentic research workflows, real-time multi-database querying, development of a molecule for a rare cancer indication and also highlight the full commercial subscription model and opportunity. For Lantern shareholders, the Nasdaq MarketSite event represents a significant milestone: the Company presenting a commercially deployed, revenue-generating AI platform directly to the institutional and analytical community that covers and invests in the biotech sector. The event is by invitation only. Investors and analysts seeking to attend or schedule a one-on-one demonstration should contact ir@lanternpharma.com. withZeta.ai at AACR 2026—Booth 5054, San Diego. Lantern Pharma will showcase withZeta.ai at the American Association for Cancer Research Annual Meeting in San Diego—one of the world’s premier oncology research and industry gatherings, attended by leading cancer researchers, clinicians, biopharma executives, and potential enterprise partners and customers. Attendees can experience the platform live at Booth 5054 across rare cancer characterization, drug discovery, combination therapy exploration, clinical trial development and analysis, and molecular optimization including for CNS related cancers. AACR 2026 marks withZeta.ai’s first major public debut before the global oncology research and drug development community—the precise audience the platform was built to serve and from which its commercial subscriber base will grow. Researchers, clinicians, and drug developers are invited to visit Booth 5054 and experience firsthand what an AI co-scientist purpose-built for rare cancers can accomplish. withZeta.ai is positioned as a force multiplier for the entire biomedical and drug development community—enabling investigators, R&D teams, biopharma companies, and global pharma enterprises to conduct in minutes or hours the research that once took weeks, months and years. Powered by a multi-agentic, multi-tool architecture and grounded in Lantern Pharma’s proprietary rare cancer ontology and knowledge-base spanning 438 cancer types, the platform simultaneously queries clinical trial databases, curated rare cancer knowledge bases, scientific literature libraries, and molecular databases—reasoning across all of them to deliver hardened, actionable insights. The platform offers three research modes—Explorer, Investigator, and Reporter—allowing users to move seamlessly from rapid hypothesis generation through deep systematic evidence synthesis to structured, publication-ready documentation. Specialized capabilities include blood-brain barrier penetration prediction via PredictBBB.ai at 94.1% accuracy and generative molecular design via the ether0 24-billion parameter AI model. Unlike general-purpose AI tools, withZeta.ai is grounded in a proprietary oncology ontology and knowledge-base that maps disease synonyms, links biomarkers to therapeutic responses, and builds hierarchical relationships between cancer subtypes—a structural advantage that took a decade to build and cannot be replicated. withZeta.ai is now commercially available with a fully enabled subscription payment model serving the full spectrum of the biomedical research and drug development community—and representing a new, non-dilutive revenue stream for Lantern Pharma shareholders. Subscription tiers include: Introductory Access: Entry-level access that puts a powerful AI co-scientist in the hands of any researcher or clinician immediately—with no barriers to getting started and no prior AI expertise required. Academic Subscription: Expanded research depth and multi-database access for academic institutions, independent investigators, and non-commercial researchers—compressing weeks of literature review into hours. Commercial Subscription: Full-platform capabilities for biotech and pharmaceutical professionals, drug discovery teams, clinical trial designers, and enterprise R&D organizations—including priority access to Lantern’s proprietary RADR® genomic response database and enterprise partnership development opportunities. Subscriptions are available immediately at withzeta.ai. The global AI drug discovery and development market is projected to grow at a compound annual growth rate exceeding 30% through 2030, with the oncology segment commanding the largest therapeutic area share. withZeta.ai’s scalable subscription model—spanning individual researchers through global pharma enterprises—is designed to capture meaningful and growing revenue across every segment of this market as the migration of scientific knowledge work to AI co-scientists accelerates.
